INTRODUCTION
On November 16, 2007, the U.S. Food and Drug Administration (FDA) approved sorafenib tosylate (Nexavar, 200-mg tablets, BAY43-9006; Bayer Pharmaceuticals Corp., Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC). This indication is based on the demonstration of improved overall survival (OS) in a large, randomized, double-blind, placebo-controlled multinational study and a supportive phase II study. The supplemental new drug application was submitted in June 2007 and received a priority review because of the observed effect on survival.
In 2005, sorafenib was first approved for the treatment of renal cell carcinoma (RCC) based on a large, multinational, placebo-controlled trial showing a longer progression-free survival with an acceptable safety profile. A regulatory review of this approval is available [1] .
CLINICAL STUDY
The FDA and the sponsors agreed under a special protocol assessment on the design and analysis of this randomized, double-blind, international, multicenter trial comparing the effects of best supportive care plus sorafenib (400 mg twice daily) with those of best supportive care plus a matching placebo in patients with unresectable HCC and no prior systemic therapy. Additional principal eligibility criteria included: pathologic confirmation of HCC; an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2; measurable disease using the Response Evaluation Criteria in Solid Tumors (RECIST); and a Child-Pugh A score. The central randomization and subsequent analyses were stratified by geographic region, performance status, and presence or absence of extrahepatic tumor. All analyses were based on the as-randomized, intention-totreat (ITT) population. The primary study endpoint was OS. The sample size was planned to demonstrate a 39% longer OS versus a control median survival estimate of 7 months with approximately 90% power, and interim analyses were prespecified with O'Brien-Fleming ␣ spending.
Secondary endpoints included the time-to-tumor progression (TTP), with a single analysis planned after 227 progression events, and objective response rate. Both of these tumor measurement assessments were performed by independent blinded radiologic review using the RECIST. Pharmacokinetic (PK) and safety evaluations were also performed. Patients gave written informed consent to be randomized to either sorafenib, taken orally, 400 mg two times daily (800 mg total daily dose) in an uninterrupted schedule, or a matching placebo. The study was conducted in accordance with the precepts established by the Helsinki Declaration and with the approval of a local human investigations committee at each site. Upon disease progression, no subsequent crossover from placebo to sorafenib was provided in the protocol, but this was an option for the data monitoring committee (DMC) to advise based on study results. Clinic visits were scheduled every 3 weeks and radiographic assessments were scheduled every 6 weeks. All patients who received any treatment were included in the safety population.
An analysis of time-to-symptomatic progression (TTSP) was initially prespecified as a coprimary endpoint because of the uncertainty about assessing radiologic response and progression in HCC and to study symptomatic outcomes independently of the radiographic results. Prior to the formal analyses, the FDA and the sponsors agreed that the TTSP analysis would be regarded as exploratory, in part because of concerns about the measurement of symptomatic changes. (Please see the FDA Guidance on patient-reported outcome measures available at http://www.fda.gov/cder/guidance/5460dft.htm.)
RESULTS
Trial enrollment began in March 2005 and was completed in April 2006. Of the total 602 patients, 299 were randomized to sorafenib and 303 were randomized to placebo. Baseline demographic and disease-related factors were well balanced between the two study arms for age, gender, race, performance status, underlying diseases, tumornode-metastasis stage, presence or absence of extrahepatic tumor (macroscopic vascular invasion or extrahepatic tumor spread), Barcelona Clinic Liver Cancer stage, and liver impairment as reflected by Child-Pugh score. Overall, 87% of patients were enrolled from European sites and 9% from North America. The median age was 67 years; 61% were aged Ն65 years, 89% were white, and 87% were male. Underlying liver diseases included hepatitis B (18%), hepatitis C (28%), and alcohol-related (26%). By Child-Pugh score, 97% were classified as A and 3% were B. Macroscopic ve-nous extension and/or extrahepatic metastases were present radiographically in 70% of the patients.
Patients could have received prior surgical or local interventional treatments. Prior treatments, also balanced between the arms, included surgical resections (20%), liverdirected therapies (40%, including radiofrequency ablation, percutaneous ethanol injection, and transarterial chemoembolization [TACE]), radiotherapy (5%), and systemic therapy (4%, primarily hormonal). Overall, 491 (82%) patients had received either prior surgery (including excisional biopsy) or prior locoregional treatments. In each group, 29% had received some form of TACE. Protocol violations were uncommon; no randomized patients were excluded from the efficacy analyses, and only three patients who did not receive study drug were excluded from the safety analyses.
Efficacy
The Kaplan-Meier OS curves are shown in Figure 1 . At the time of the second planned interim analysis of OS in October 2006, there were 321 deaths, 143 on sorafenib and 178 on placebo. The hazard ratio for sorafenib versus placebo was 0.69 (95% confidence interval [CI], (0.55, 0.87)), and the stratified log-rank test nominal p-value was 0.00058. (For this interim analysis, the associated ␣ was 0.0073.) The median OS time for sorafenib was 10.7 months, versus 7.9 months for the placebo group (Table 1) . The DMC then advised the sponsor to Figure 1 . Kaplan-Meier curves for overall survival in the phase III hepatocellular carcinoma trial. At the second interim survival analysis for the intention-to-treat population, with 44.5% of events in the sorafenib group and 55.5% of events in the placebo group, the hazard ratio for sorafenib versus placebo was 0.69 [95% confidence interval, (0.55, 0.87)], and the stratified log-rank test p-value was 0.00058. Stratified log-rank test (for the interim analysis of survival, the stopping boundary one-sided ␣ ϭ 0.0073). Stratification factors were geographic region, performance status, and presence or absence of extrahepatic tumor. c The TTP analysis, based on independent radiologic review, was performed at an earlier time point than the survival analysis. Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival; TTP, time to progression. stop the study on the basis of the positive efficacy findings in conjunction with acceptable safety. The sponsor agreed, and all patients remaining in the placebo arm were offered the option to receive sorafenib. Because the study was stopped and all patients were offered sorafenib, this result was considered the final study analysis for OS.
In May 2006, based on 263 radiologic progression events determined by independent blinded radiologic review, the sponsor conducted the prespecified analysis of TTP. There were 107 progression events on sorafenib and 156 on placebo. The hazard ratio for TTP for sorafenib versus placebo was 0.58 [95% CI, (0.45, 0.74)], and the logrank test nominal p-value was 0.000007.
The response rate also was based on the independent radiologic review of the ITT population. There were no complete responses; RECIST-confirmed partial responses (PRs) were reported for seven (2.3%) sorafenib patients and two (0.7%) placebo patients. Response durations are not available because of censoring at the time of analysis. By investigator assessment of the RECIST response, 18 (6.0%) sorafenib patients and eight (2.6%) placebo patients were judged as confirmed PRs.
The median treatment duration was 18.6 weeks for placebo and 23 weeks for sorafenib. Based on pill counts at visits, the sponsor estimated that, overall, 284 (94%) patients in the placebo group and 227 (76%) patients in the sorafenib group received an average daily dose of at least 80% of the planned daily dose. The dose of study drug was reduced in 39 (13%) patients in the placebo group and in 96 (32%) patients in the sorafenib group.
Safety
Comparing the placebo-treated group with the sorafenibtreated group (placebo versus sorafenib), there were more serious adverse events (AEs) (54% versus 51%), more AEs leading to permanent drug discontinuation (35% versus 32%), and more deaths within 30 days of receiving the study drug (32% versus 23%) in the placebo group. For sorafenib-treated patients, cardiac ischemia or infarction was reported in 2.7%, versus 1.3% of placebo-treated patients. Among the AEs reported more frequently overall in patients in the sorafenib arm (Table 2) , diarrhea occurred in 55% (grade Ն3, 10%), hand-foot skin reaction occurred in 21% (grade Ն3, 8%), and hy- Nausea  24  1  0  20  3  0  Vomiting  15  2  0  11  2  0  Constipation  14  0  0  10  0  0  Hepatobiliary/pancreas  Liver dysfunction  11  2  1  8  2  1  Pain  Pain, abdomen  31  9  0  26  5  1 Abbreviations: HCC, hepatocellular carcinoma; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.
pertension occurred in 9% (grade 3, 4%). Considering the severe AEs (grade Ն3) that occurred more frequently among the sorafenib-treated patients, hypertension, diarrhea, and hand-foot skin reaction were notable (Table 3) . Hemorrhage was not more frequent in the sorafenib group. Hemorrhage/bleeding was reported in 18% of sorafenib patients and 20% of placebo patients. The rates of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 and 4 bleeding were also higher in the placebo group (CTCAE grade 3/4, 3%/2% on sorafenib and 5%/4% on placebo). Bleeding from esophageal varices was reported in 2.4% of sorafenib-treated patients and 4% of placebo-treated patients. Serious AEs were reported more frequently among the placebo-treated patients than among those in the sorafenib arm; vascular thrombosis/embolism was reported in three patients in each group. Among the laboratory abnormalities, hypophosphatemia occurred in 35% (grade 3, 11%) of sorafenib patients versus 11% (grade 3, 2%) of placebo patients. Lipase and amylase elevations were common (30%-40% of patients) and usually transient, but were not more frequent in the sorafenib group. Thrombocytopenia was observed overall in 46% of sorafenib-treated patients and 41% of placebo patients; CTCAE grade 3-4 thrombocytopenia was reported in 4% of sorafenib-treated patients and Ͻ1% of placebo-treated patients. International normalized ratio (INR) elevations were observed in 42% of sorafenib-treated patients and 34% of placebo-treated patients. There were no CTCAE grade 4 INR elevations observed in either group. Most adverse reactions were managed by a dose reduction or temporary interruption. Of the 297 patients treated with sorafenib, four discontinued treatment permanently because of hand-foot syndrome and one discontinued treatment permanently because of hypertension. The most common events resulting in a dose reduction in the sorafenib group were diarrhea in 23 patients (7.7%), hand-foot skin reaction in 16 patients (5.4%), rash in nine patients (3.0%), and fatigue in six patients (2.0%). Overall, fatigue was more common in the placebo group than in the sorafenib-treated patients.
Because this HCC study and the earlier RCC study both used the same sorafenib dose and schedule against a placebo control arm, the FDA performed an exploratory crossstudy evaluation of severe (grade Ն3) AEs reported for sorafenib. The frequencies of severe adverse events were similar in the two studies (Table 4) .
The FDA and the applicant had agreed on a series of PK assessments to explore the effects of race, hepatic impairment, and drug-drug interactions for sorafenib. The FDA also independently analyzed the raw datasets obtained from these studies. The effect of race was evaluated in healthy subjects given a single 400-mg dose. Among the 40 Japanese, 38 Chinese, and 40 white patients enrolled, the area under the plasma concentration versus time curve (AUC) for sorafenib was 30% lower in Asians (both Japanese and Chinese) than in whites.
Sorafenib is eliminated primarily by metabolism in the liver mediated by cytochrome P-450 (CYP)3A4 and UDPglucuronosyltransferase (UGT)1A9. However, in a crossstudy evaluation with healthy subjects, sorafenib AUCs were 23%-65% lower in HCC patients with mild (ChildPugh A) and moderate (Child-Pugh B) hepatic impairment. In patients with HCC, the PK of sorafenib was similar between groups with Child-Pugh A and B impairment, and no dose adjustment appears necessary between these two groups. The PK of sorafenib in patients with Child-Pugh C hepatic impairment has not been studied. Renal impairment did not alter the PK of sorafenib. Abbreviations: NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NOS, not otherwise specified. 
